-
Tytuł:
-
Implications of antibiotics use during the COVID-19 pandemic: present and future.
-
Autorzy:
-
Miranda C; Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.; Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.; Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, Lisboa, Caparica, Portugal.
Silva V; Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.; Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, Lisboa, Caparica, Portugal.; Department of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.; Functional Genomics and Proteomics Unit, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.
Capita R; Department of Food Hygiene and Technology, Veterinary Faculty, University of León, León, Spain.; Institute of Food Science and Technology, University of León, León, Spain.
Alonso-Calleja C; Department of Food Hygiene and Technology, Veterinary Faculty, University of León, León, Spain.; Institute of Food Science and Technology, University of León, León, Spain.
Igrejas G; Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, Lisboa, Caparica, Portugal.; Department of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.; Functional Genomics and Proteomics Unit, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.
Poeta P; Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.; Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal.; Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, Lisboa, Caparica, Portugal.
-
Źródło:
-
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2020 Dec 01; Vol. 75 (12), pp. 3413-3416.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 1997- : London : Oxford University Press
Original Publication: London, New York, Academic Press.
-
MeSH Terms:
-
Betacoronavirus*
Anti-Infective Agents/*therapeutic use
Coronavirus Infections/*epidemiology
Pneumonia, Viral/*epidemiology
COVID-19 ; Drug Resistance, Bacterial ; Global Health ; Health Policy ; Humans ; One Health ; Pandemics ; Population Surveillance ; SARS-CoV-2
-
References:
-
Microb Drug Resist. 2004 Spring;10(1):65-9. (PMID: 15140396)
N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
Indian J Pediatr. 2020 Apr;87(4):281-286. (PMID: 32166607)
Antibiotics (Basel). 2019 Oct 31;8(4):. (PMID: 31683590)
Trans R Soc Trop Med Hyg. 2017 Jun 1;111(6):255-260. (PMID: 29044373)
Aging (Albany NY). 2020 Mar 30;12(8):6511-6517. (PMID: 32229706)
Front Microbiol. 2019 Apr 01;10:539. (PMID: 30988669)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
China CDC Wkly. 2020 Feb 21;2(8):113-122. (PMID: 34594836)
Pak J Med Sci. 2020 May;36(COVID19-S4):S6-S11. (PMID: 32582306)
PLoS Med. 2016 Nov 29;13(11):e1002184. (PMID: 27898664)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Lancet Respir Med. 2020 May;8(5):475-481. (PMID: 32105632)
Int J Antimicrob Agents. 2020 Jul;56(1):105949. (PMID: 32205204)
ACS Infect Dis. 2015 Jul 10;1(7):317-26. (PMID: 27622822)
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):173-176. (PMID: 32164081)
Infect Dis (Lond). 2020 Jun;52(6):427-429. (PMID: 32233816)
J Antimicrob Chemother. 2020 Jul 1;75(7):1681-1684. (PMID: 32433765)
Zoonoses Public Health. 2015 Nov;62(7):534-42. (PMID: 25639901)
Pathog Dis. 2019 Dec 1;77(9):. (PMID: 32065221)
Nat Microbiol. 2020 Apr;5(4):536-544. (PMID: 32123347)
Lancet. 2016 Jan 9;387(10014):168-75. (PMID: 26603918)
Prehosp Disaster Med. 2020 Apr;35(2):119. (PMID: 32167445)
Methods Mol Biol. 2015;1282:1-23. (PMID: 25720466)
-
Substance Nomenclature:
-
0 (Anti-Infective Agents)
-
Entry Date(s):
-
Date Created: 20200825 Date Completed: 20201127 Latest Revision: 20240329
-
Update Code:
-
20240329
-
PubMed Central ID:
-
PMC7499579
-
DOI:
-
10.1093/jac/dkaa350
-
PMID:
-
32830266
-
COVID-19 is caused by the SARS-CoV-2 virus, which has infected more than 4 million people with 278 892 deaths worldwide as of 11 May 2020. This disease, which can manifest as a severe respiratory infection, has been declared as a public health emergency of international concern and is being treated with a variety of antivirals, antibiotics and antifungals. This article highlights the administration of antimicrobials in COVID-19 patients worldwide, during the 2019-20 pandemic. It is imperative to be aware of the unreported amounts of antibiotics that have been administered worldwide in just a few months and a marked increase in antimicrobial resistance should therefore be expected. Due to the lack of data about antimicrobial use during this pandemic, the global impact on the emergence of new antimicrobial resistance is as yet unknown. This issue must be at the forefront of public health policymaking and planning in order that we are prepared for the potentially severe consequences for human and animal health and the environment.
(© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
